Rising Senior Populations And Industry Consolidation Will Support Long Term Pharmacy Demand

Catalysts

About Guardian Pharmacy Services

Guardian Pharmacy Services operates a national network of long term care pharmacies focused on assisted living and other senior care settings.

What are the underlying business or industry changes driving this perspective?

• Growing senior and high acuity populations in assisted living facilities should support sustained mid to high single digit organic resident growth and increasingly complex drug regimens, expanding revenue per resident and total revenue.
• Rising consolidation among assisted living facility operators is likely to favor scaled, specialized providers, allowing Guardian to deepen national partnerships, win multi-state contracts and improve route density, which should support higher margins and earnings.
• Continued maturation of the 2 to 5 year pharmacy cohorts and optimization of recently acquired and greenfield locations are expected to lift location level profitability, narrowing the current 80 basis point margin drag and enhancing adjusted EBITDA margin and earnings growth.
• Active but disciplined M&A, supported by a debt free balance sheet, strong cash conversion above 60% and a flexible shelf registration, positions Guardian to accelerate regional density and national scale, driving incremental revenue and operating leverage.
• Ongoing negotiations with payers, potential evolution toward more value based arrangements and demonstrated ability to offset policy headwinds such as those tied to the Inflation Reduction Act should stabilize reimbursement, protect net margins and support durable EPS growth.

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Guardian Pharmacy Services's revenue will grow by 5.8% annually over the next 3 years.
• Analysts assume that profit margins will increase from 1.3% today to 5.3% in 3 years time.
• Analysts expect earnings to reach $86.5 million (and earnings per share of $1.38) by about December 2028, up from $17.5 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $102.1 million in earnings, and the most bearish expecting $67.7 million.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 30.5x on those 2028 earnings, down from 108.4x today. This future PE is greater than the current PE for the US Healthcare industry at 22.4x.
• Analysts expect the number of shares outstanding to grow by 0.05% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 6.96%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Policy and reimbursement changes tied to Medicare Part D and the Inflation Reduction Act could prove more disruptive than anticipated if negotiations with PBMs and payers fail to fully offset headwinds over time. This would pressure revenue growth and adjusted EBITDA margins and ultimately limit earnings expansion.
• Given management expects reported revenue growth to be relatively flat in 2026 despite powerful demographic tailwinds, any prolonged slowdown in assisted living resident admissions or seasonal reluctance to move loved ones into facilities could weaken the pace of organic resident growth. This would dampen revenue and constrain operating leverage.
• The strategy depends heavily on integrating a robust pipeline of acquisitions and greenfield startups. If newly acquired or contiguous locations take longer than the expected four years to reach mature profitability, the current 80 basis point drag from recent investments could increase and structurally cap EBITDA margins and earnings growth.
• Industry consolidation among assisted living facility operators and shifts toward value based models may increase bargaining power for large payers and customers. If Guardian is forced into less favorable contract terms or higher performance risk without commensurate upside, this could compress net margins and create volatility in earnings.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $34.0 for Guardian Pharmacy Services based on their expectations of its future earnings growth, profit margins and other risk factors.
  
• In order for you to agree with the analysts, you'd need to believe that by 2028, revenues will be $1.6 billion, earnings will come to $86.5 million, and it would be trading on a PE ratio of 30.5x, assuming you use a discount rate of 7.0%.
  
• Given the current share price of $29.92, the analyst price target of $34.0 is 12.0% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.